Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
European Organization for Research and Treatment of Cancer |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00002555 |
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if radiation therapy plus chemotherapy is more effective than radiation therapy alone in treating patients with head and neck cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of high-dose radiation therapy alone with high-dose radiation therapy plus cisplatin in treating patients with head and neck cancer who have undergone surgery to remove the cancer.
Condition | Intervention | Phase |
---|---|---|
Head and Neck Cancer |
Drug: cisplatin Radiation: low-LET cobalt-60 gamma ray therapy Radiation: low-LET electron therapy Radiation: low-LET photon therapy |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized |
Official Title: | A PHASE III RANDOMIZED STUDY ON POSTOPERATIVE RADIO- AND CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK CARCINOMAS |
Estimated Enrollment: | 338 |
Study Start Date: | February 1994 |
OBJECTIVES: I. Determine whether the addition of cisplatin to high-dose postoperative radiotherapy increases the disease-free survival rate of patients with locally advanced head and neck carcinomas at high risk of recurrence following radical surgery.
OUTLINE: Randomized study. Patients are registered and randomized to treatment within 25 days of surgery. Arm I:
Radiotherapy. Irradiation of the preoperative primary tumor site with a boost to areas at high risk for recurrence using Co60 equipment, 4-6 MV linear accelerators, or 6-12 MeV electrons. Arm II: Radiotherapy plus Single-Agent Chemotherapy. Irradiation as in Arm I; plus Cisplatin, CDDP, NSC-119875.
PROJECTED ACCRUAL: A total of 338 evaluable patients will be studied.
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS: Histologically confirmed squamous cell carcinoma of the head and neck of the following sites: Oral cavity Oropharynx Hypopharynx (only if ineligible for protocol EORTC-24891) Larynx T3-4, any N, M0 or any T, N2-3, M0 disease (UICC staging) resected with curative intent T3, N0 carcinoma of the larynx with suitable microscopically clear margins is ineligible At least one of the following high-risk characteristics required: Histopathologically positive surgical margins No gross residual disease Perineural involvement Extranodal spread of disease Oral cavity or oropharyngeal lesions with metastatic nodes at level 4 or 5 Vascular embolisms in the neck No metastases at diagnosis No known CNS disease
PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: WHO 0-2 Hematopoietic: WBC at least 4,000 Platelets at least 100,000 Hemoglobin normal (at least 6.8 mmoles/liter) Hepatic: Bilirubin no greater than 2 times normal Other liver function tests no greater than 2 times normal Renal: Creatinine no greater than 1.3 mg/dL (120 micromoles/liter) Creatinine clearance greater than 60 mL/min Other: No active, uncontrolled infection No requirement for antibiotics that might interfere with platinum excretion No requirement for drugs affecting bone marrow function (e.g., lithium, corticosteroids) No medical condition precluding postoperative chemotherapy No prior or concurrent malignancy other than nonmelanomatous skin cancer
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior locoregional radiotherapy to the head and neck Surgery: Excision with curative intent required
Belgium | |
Institut Jules Bordet | |
Brussels, Belgium, 1000 | |
France | |
Centre de Lute Contre le Cancer,Georges-Francois Leclerc | |
Dijon, France, 21079 | |
Centre Oscar Lambret | |
Lille, France, 59020 | |
CHR de Grenoble - La Tronche | |
Grenoble, France, 38043 | |
CRLCC Nantes - Atlantique | |
Nantes-Saint Herblain, France, 44805 | |
Hopital Jean Bernard | |
Poitiers, France, 86021 | |
Institut Gustave Roussy | |
Villejuif, France, F-94805 | |
Italy | |
Istituti Fisioterapici Ospitalieri - Roma | |
Rome, Italy, 00161 | |
Istituto Nazionale per lo Studio e la Cura dei Tumori | |
Milan, Italy, 20133 | |
Netherlands | |
University Medical Center Nijmegen | |
Nijmegen, Netherlands, NL-6252 HB | |
Poland | |
Medical University of Gdansk | |
Gdansk, Poland, 80-211 | |
Slovenia | |
Institute of Oncology, Ljubljana | |
Ljubljana, Slovenia, Sl-1000 | |
Spain | |
Ciudad Sanitaria Vall D'Hebron | |
Barcelona, Spain, 08035 | |
Switzerland | |
Centre Hospitalier Universitaire Vaudois | |
Lausanne, Switzerland, CH-1011 | |
Inselspital, Bern | |
Bern, Switzerland, CH-3010 | |
Ospedale San Giovanni | |
Bellinzona, Switzerland, CH-6500 | |
Universitaetsspital | |
Zurich, Switzerland, CH-8091 | |
Turkey | |
Dokuz Eylul University School of Medicine | |
Izmir, Turkey, 35340 | |
United Kingdom, England | |
Nottingham City Hospital NHS Trust | |
Nottingham, England, United Kingdom, NG5 1PB |
Study Chair: | Jacques Bernier, MD, PhD | Oncology Institute of Southern Switzerland |
Study ID Numbers: | CDR0000063431, EORTC-22931 |
Study First Received: | November 1, 1999 |
Last Updated: | February 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00002555 History of Changes |
Health Authority: | United States: Federal Government |
stage III squamous cell carcinoma of the lip and oral cavity stage IV squamous cell carcinoma of the lip and oral cavity stage III squamous cell carcinoma of the oropharynx stage IV squamous cell carcinoma of the oropharynx |
stage III squamous cell carcinoma of the hypopharynx stage IV squamous cell carcinoma of the hypopharynx stage III squamous cell carcinoma of the larynx stage IV squamous cell carcinoma of the larynx |
Cisplatin Laryngeal Carcinoma Cobalt Head and Neck Neoplasms Epidermoid Carcinoma |
Squamous Cell Carcinoma Carcinoma, Squamous Cell Hypopharyngeal Cancer Carcinoma |
Neoplasms Neoplasms by Site Head and Neck Neoplasms |